EUVIMEDEUVIMED entdecken
Multizentrische Studie

Association of neoadjuvant chemotherapy dose intensity with pathological complete response and event-free survival in HER2-negative early breast cancer

Roberto Buonaiuto, Federica Martorana, Paola Marino, Federica Mangiacotti, Aldo Caltavituro, Francesco La Spina, Paola Trasacco, Alessandra Longobardi, Vittoria Molinaro, Maria Letizia Cataldo, Martina Pagliuca, Michelino De Laurentiis und 4 weitere

European Journal of Cancer · 2026-01 · 232 · 116102

DOI: 10.1016/j.ejca.2025.116102 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2026-01. Verfasst von Roberto Buonaiuto und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Thoracic Oncology, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale, Via Mariano Semmola, 52, Napoli 80131, Italy; Cli…. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyBreast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsTriple Negative Breast NeoplasmsHumansFemaleMiddle AgedRetrospective StudiesErb-b2 Receptor Tyrosine KinasesAdultAgedChemotherapy, AdjuvantDose-Response Relationship, Drug

Stichwörter der Autor:innen

Breast cancerDose delaysDose reductionNeoadjuvant chemotherapyRelative dose intensity

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, human

Autor:innen und Institutionen

  • Department of Breast and Thoracic Oncology, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale, Via Mariano Semmola, 52, Napoli 80131, Italy; Clinical and Translational Oncology, Scuola Superiore Meridionale, Via Me…
  • Humanitas Istituto Clinico Catanese, SP54, Contrada Cubba Marletta 11, Misterbianco, Catania 95045, Italy; Medical Oncology Department, Azienda Ospedaliero Universitaria Policlinico G. Rodolico, San Marco, Via Santa Sof…
  • Dipartimento di Patologia Umana e dell'Adulto e dell'Età Evolutiva "G. Barresi", AOU Policlinico G. Martino - Università di Messina, Via Consolare Valeria 1, Messina 98125, Italy.
  • Oncology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Sergio Pansini 5, Napoli 80131, Italy.
  • Clinical and Translational Oncology, Scuola Superiore Meridionale, Via Mezzocannone 4, Napoli 80138, Italy; Oncology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Sergio Pansin…
  • Humanitas Istituto Clinico Catanese, SP54, Contrada Cubba Marletta 11, Misterbianco, Catania 95045, Italy.

Zitieren

APA

Buonaiuto, R., Martorana, F., Marino, P., Mangiacotti, F., Caltavituro, A., La Spina, F., Trasacco, P., Longobardi, A., Molinaro, V., Cataldo, M. L., Pagliuca, M., De Laurentiis, M., Giuliano, M., Arpino, G., Vigneri, P., & De Angelis, C. (2026). Association of neoadjuvant chemotherapy dose intensity with pathological complete response and event-free survival in HER2-negative early breast cancer. European Journal of Cancer, 232, 116102. https://doi.org/10.1016/j.ejca.2025.116102

Vancouver

Buonaiuto R, Martorana F, Marino P, Mangiacotti F, Caltavituro A, La Spina F, et al. Association of neoadjuvant chemotherapy dose intensity with pathological complete response and event-free survival in HER2-negative early breast cancer. European Journal of Cancer. 2026;232:116102. doi:10.1016/j.ejca.2025.116102

BibTeX
@article{Buonaiuto2026,
  author = {Buonaiuto, Roberto and Martorana, Federica and Marino, Paola and Mangiacotti, Federica and Caltavituro, Aldo and La Spina, Francesco and Trasacco, Paola and Longobardi, Alessandra and Molinaro, Vittoria and Cataldo, Maria Letizia and Pagliuca, Martina and De Laurentiis, Michelino and Giuliano, Mario and Arpino, Grazia and Vigneri, Paolo and De Angelis, Carmine},
  title = {Association of neoadjuvant chemotherapy dose intensity with pathological complete response and event-free survival in HER2-negative early breast cancer},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {232},
  pages = {116102},
  doi = {10.1016/j.ejca.2025.116102}
}
Kostenlos starten →